Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633527 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT02633527 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 222 participants.
The verdict
NCT02633527, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with ADHD.
Interventions
- DRUG Placebo
- DRUG 100mg SPN-812
- DRUG 400mg SPN-812
- DRUG 200mg SPN-812
- DRUG 300mg SPN-812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2016-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633527
The ClinicalTrials.gov registry entry for NCT02633527 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02633527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02633527 about?
NCT02633527 is a clinical study titled "Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD". This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with ADHD.
What is the current status of trial NCT02633527?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2016-02-01. Estimated completion is 2016-07-25.
What interventions are being tested in trial NCT02633527?
The interventions under investigation include: Placebo (DRUG), 100mg SPN-812 (DRUG), 400mg SPN-812 (DRUG), 200mg SPN-812 (DRUG), 300mg SPN-812 (DRUG).
Who is sponsoring clinical trial NCT02633527?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.